The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
A common pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells
Open accessAbstract
The epothilones are naturally occurring antimitotic drugs that share with the taxanes a similar mechanism of action without apparent structural similarity. Although photoaffinity labeling and electron crystallographic studies have identified the taxane-binding site on β-tubulin, similar data are not available for epothilones. To identify tubulin residues important for epothilone binding, we have isolated two epothilone-resistant human ovarian carcinoma sublines derived in a single-step selection with epothilone A or B. These epothilone-resistant sublines exhibit impaired epothilone- and taxane-driven tubulin polymerization caused by acquired β-tubulin mutations (β274 Thr→Ile and β282 Arg→Gln ) located in the atomic model of αβ-tubulin near the taxane-binding site. Using molecular modeling, we investigated the conformational behavior of epothilone, which led to the identification of a common pharmacophore shared by taxanes and epothilones. Although two binding modes for the epothilones were predicted, one mode was identified as the preferred epothilone conformation as indicated by the activity of a potent pyridine-epothilone analogue. In addition, the structure–activity relationships of multiple taxanes and epothilones in the tubulin mutant cells can be fully explained by the model presented here, verifying its predictive value. Finally, these pharmacophore and activity data from mutant cells were used to model the tubulin binding of sarcodictyins, a distinct class of microtubule stabilizers, which in contrast to taxanes and the epothilones interact preferentially with the mutant tubulins. The unification of taxane, epothilone, and sarcodictyin chemistries in a single pharmacophore provides a framework to study drug–tubulin interactions that should assist in the rational design of agents targeting tubulin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure of the αβ tubulin dimer by electron crystallography
Nogales, E., Wolf, S. G., & Downing, K. H. (1998) · Nature · doi:10.1038/34465 · Cited by 2,076
Self-citationHigh-Resolution Model of the Microtubule
Nogales, E., Whittaker, M., Milligan, R. A., & Downing, K. H. (1999) · Cell · doi:10.1016/s0092-8674(00)80961-7 · Cited by 1,195
Self-citationEpothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action.
Bollag, D. M., McQueney, P. A., Zhu, J., Hensens, O. D., Koupal, L. R., Liesch, J. M., Goetz, M., Lazarides, E., & Woods, C. M. (1995) · PubMed · Cited by 685
Giannakakou, P., Sackett, D. L., Kang, Y.-K., Zhan, Z., Buters, J. T. M., Fojo, T., & Poruchynsky, M. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.27.17118 · Cited by 681
Self-citationMicrotubules and actin filaments: dynamic targets for cancer chemotherapy
Jordan, M. A., & Wilson, L. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80095-1 · Cited by 614
Höfle, G., Bedorf, N., Steinmetz, H., Schomburg, D., Gerth, K., & Reichenbach, H. (1996) · Angewandte Chemie International Edition in English · doi:10.1002/anie.199615671 · Cited by 515
Kowalski, R. J., Giannakakou, P., & Hamel, E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.4.2534 · Cited by 511
Self-citationSynthesis of epothilones A and B in solid and solution phase
Nicolaou, K. C., Winssinger, N., Pastor, J., Ninkovic, S., Sarabia, F., He, Y., Vourloumis, D., Yang, Z., Li, T., Giannakakou, P., et al. (1997) · Nature · doi:10.1038/387268a0 · Cited by 400
Self-citationSullivan, K. F., & Cleveland, D. W. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4327 · Cited by 400
Discodermolide, A Cytotoxic Marine Agent That Stabilizes Microtubules More Potently Than Taxol,
ter Haar, E., Kowalski, R. J., Hamel, E., Lin, C. M., Longley, R. E., Gunasekera, S. P., Rosenkranz, H. S., & Day, B. W. (1996) · Biochemistry · doi:10.1021/bi9515127 · Cited by 382
Paclitaxel Resistance in Non–Small-Cell Lung Cancer Associated With Beta-Tubulin Gene Mutations
Monzó, M., Rosell, R., Sánchez, J. J., Lee, J. S., O'Brate, A., González-Larriba, J. L., Alberola, V., Lorenzo, J. C., Núñez, L., Ro, J. Y., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.6.1786 · Cited by 306
Kowalski, R. J., Giannakakou, P., Gunasekera, S. P., Longley, R. E., Day, B. W., & Hamel, E. (1997) · Molecular Pharmacology · doi:10.1124/mol.52.4.613 · Cited by 262
Self-citationA common pharmacophore for cytotoxic natural products that stabilize microtubules
Ojima, I., Chakravarty, S., Inoue, T., Lin, S., He, L., Horwitz, S. B., Kuduk, S. D., & Danishefsky, S. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4256 · Cited by 250
3'-(p-azidobenzamido)taxol photolabels the N-terminal 31 amino acids of beta-tubulin.
Rao, S., Krauss, N. E., Heerding, J. M., Swindell, C. S., Ringel, I., Orr, G. A., & Horwitz, S. B. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41836-9 · Cited by 245
Characterization of the Taxol Binding Site on the Microtubule
Rao, S., Orr, G. A., Chaudhary, A. G., Kingston, D. G. I., & Horwitz, S. B. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.35.20235 · Cited by 235
Conformational changes of small molecules binding to proteins
Nicklaus, M. C., Wang, S., Driscoll, J. S., & Milne, G. W. A. (1995) · Bioorganic & Medicinal Chemistry · doi:10.1016/0968-0896(95)00031-b · Cited by 229
Long, B. H., Carboni, J. M., Wasserman, A. J., CORNELL, L., Casazza, A. M., Jensen, P. R., Lindel, T., Fenical, W., & Fairchild, C. R. (1998) · PubMed · Cited by 218
Taxol: The chemistry and structure-activity relationships of a novel anticancer agent
Kingston, D. G. I. (1994) · Trends in Biotechnology · doi:10.1016/0167-7799(94)90120-1 · Cited by 169
Su, D., Meng, D., Bertinato, P., Balog, A., Sorensen, E. J., Danishefsky, S. J., Zheng, Y., Chou, T., He, L., & Horwitz, S. B. (1997) · Angewandte Chemie International Edition in English · doi:10.1002/anie.199707571 · Cited by 164
Hamel, E., Sackett, D. L., Vourloumis, D., & Nicolaou, K. C. (1999) · Biochemistry · doi:10.1021/bi983023n · Cited by 159
Self-citationSolid and Solution Phase Synthesis and Biological Evaluation of Combinatorial Sarcodictyin Libraries
Nicolaou, K. C., Winssinger, N., Vourloumis, D., Ohshima, T., Kim, S., Pfefferkorn, J. A., Xu, J.-Y., & Li, T. (1998) · Journal of the American Chemical Society · doi:10.1021/ja9823870 · Cited by 132
Self-citationTotal Synthesis of Sarcodictyins A and B
Nicolaou, K. C., Xu, J. Y., Kim, S., Pfefferkorn, J. A., Ohshima, T., Vourloumis, D., & Hosokawa, S. (1998) · Journal of the American Chemical Society · doi:10.1021/ja981062g · Cited by 95
Self-citationCancer drugs better than taxol?
Cowden, C. J. (1997) · Nature · doi:10.1038/387238a0 · Cited by 28
Cited by
Microtubules as a target for anticancer drugs
Jordan, M. A., & Wilson, L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1317 · Cited by 4,000
Paul Ehrlich's magic bullet concept: 100 years of progress
Strebhardt, K., & Ullrich, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2394 · Cited by 1,457
Mechanisms of Taxol resistance related to microtubules
Orr, G. A., Verdier-Pinard, P., McDaid, H., & Horwitz, S. B. (2003) · Oncogene · doi:10.1038/sj.onc.1206934 · Cited by 727
Microtubule-targeted anticancer agents and apoptosis
Bhalla, K. N. (2003) · Oncogene · doi:10.1038/sj.onc.1207233 · Cited by 461
Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC
Chang, A. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2010.08.022 · Cited by 443
Metadata
- Authors
- Giannakakou, P., Gussio, R., Nogales, E., Downing, K. H., Zaharevitz, D., Bollbuck, B., Poy, G., Sackett, D., Nicolaou, K. C., & Fojo, T.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2000-02-25
- Volume
- 97
- Issue
- 6
- Pages
- 2904-2909
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2107607807
- Cited by
- 477
- References
- 23
- FWCI
- 11.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.